Navigating the grey zone: Jean-Sébastien Dupont on GenAI and Canadian copyright law with Canadian Lawyer
In a recent article published by Canadian Lawyer, Jean-Sébastien Dupont discusses the challenges introduced by generative AI (GenAI) in the context of Canadian copyright law. As GenAI technologies evolve rapidly, issues around ownership and copyright infringement become increasingly pressing.
Jean-Sébastien emphasizes a key principle in copyright law, stating, “What you can protect is the expression of an idea, not the idea itself”. One of the main challenges with GenAI tools is that they are trained on massive datasets including copyrighted works. These tools, which can imitate a distinctive style, may come dangerously close to replicating an original work. “The question with GenAI is whether its outputs cross that line”, he adds.
Regarding the statutory nature of Canadian copyright law, Jean-Sébastien notes, “Judges interpret the law as it’s written; they don’t create it. So, we’re operating in a legal grey zone until Parliament steps in or courts issue clear rulings”. As GenAI continues to evolve, the discussion around how Canadian copyright law adapts, particularly regarding the distinction between inspiration and infringement, remains crucial.
Read the full article via the Canadian Lawyer website.
Related News & Media
-
Melanie Szweras on certifying data breach class actions for Lexpert
Recently, Principal Melanie Szweras spoke with Jessica Mach from Lexpert on some of the challenges that arise in certifying data breach class actions.Read More -
Melanie Szweras and Patrick Roszell talk AI and Health Privacy with Lexpert
Recently Smart & Biggar Principals Patrick Roszell and Melanie Szweras sat down with Lexpert’s Zena Olijnyk to discuss the privacy impacts caused by the increasing use of artificial intelligence (...Read More -
Noel Courage quoted in Lexpert on licensing gains as patent expiries loom
Smart & Biggar Principal Noel Courage recently discussed licensing trends with Lexpert, noting that start-ups and academic institutions remain key innovation sources in the pharma and biopharmaceu...Read More